世界の肝線維症市場 – 業界動向と2029年までの予測

Get Exclusive Sample PDF of this Report Here

市場分析と規模

近年、肝線維症市場は予測期間中に急速に成長すると予想されています。2019年の調査「世界の肝臓疾患の負担」によると、肝臓疾患は世界中で約200万人の死因となっており、そのうち100万人は肝硬変の合併症、100万人はウイルス性肝炎および肝細胞癌によるものです。医療従事者は、肝線維症の根本的な原因に対処して肝臓の瘢痕化を予防または遅らせることで、肝線維症の治療に注力しています。慢性的なアルコール摂取、自己免疫性肝炎、ウィルソン病、ガラクトース血症、フルクトース血症、グリコーゲン貯蔵疾患、鉄過剰症状、ゴーシェ病、細菌、寄生虫、ウイルス感染などの貯蔵および代謝障害、および肝血流に影響を与える障害などはすべて、肝線維症管理の考えられるリスク要因です。

Data Bridge Market Research の分析によると、肝線維症市場は 2021 年に 164.5 億米ドルと評価され、2029 年までに 387.4 億米ドルに達し、2022 年から 2029 年の予測期間中に 11.30% の CAGR を記録すると予想されています。Data Bridge Market Research チームがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みが含まれています。

市場の定義

肝臓障害が繰り返し起こったり持続したりすると、肝臓に異常に多くの瘢痕組織が形成され、これを肝線維症といいます。線維症には症状はありませんが、瘢痕が広範囲に及ぶと肝硬変を引き起こし、症状を引き起こします。医療従事者は、血液検査や画像検査で症状の重症度を判断し、肝生検を行います。医療従事者は肝線維症の原因の治療に重点を置きます。これにより、肝臓の瘢痕化がさらに進行するのを止めたり遅らせたりして、より良い結果につながります。抗ウイルス薬や胆管の閉塞の除去や溶解は、いずれも肝線維症の潜在的な治療法です。

レポートの範囲と市場セグメンテーション

Get Exclusive Sample PDF of this Report Here

肝線維症市場の動向

ドライバー

• 肝線維症の罹患率の増加

世界中で肝線維症の罹患率が上昇していることから、市場の成長が促進されると予測されています。これに伴い、慢性 B 型肝炎や C 型肝炎の感染、HIV の同時感染による免疫力の低下、肝臓移植後の免疫抑制剤の使用などのリスク要因の罹患率の急増も、肝線維症市場の拡大につながると予測されています。

• 医療インフラへの投資増加

肝線維症市場の成長率に影響を与えるもう一つの重要な要因は、インフラの改善に役立つ医療費の増加です。また、さまざまな政府機関が資金を増やすことで医療インフラの改善を目指しており、これが市場の動向にさらに影響を与えるでしょう。

• 高齢者人口の増加

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to liver fibrosis, further estimated to enhance the 'market's growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the liver fibrosis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and rising disposable income will result in the expansion of liver fibrosis market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the liver fibrosis market growth. Along with this, rising drug approvals and launches will further propel the 'market's growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the liver fibrosis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the liver fibrosis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This liver fibrosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the liver fibrosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Liver fibrosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Liver Fibrosis Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the liver fibrosis market.

Recent Development

• In January 2022, Siemens Healthineers announced the launch of the Enhanced Liver Fibrosis (ELF) Test in the U.S. this test offers broad clinical access to the minimally invasive prognostic tool. The ELF Test is a simple, efficient blood test for determining prognosis in individuals with advanced fibrosis (F3 or F4) caused by non-alcoholic steatohepatitis (NASH), a kind of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation.

Global Liver Fibrosis Market Scope

The liver fibrosis market is segmented on the basis of condition, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Condition

• Chronic Liver Diseases
• Hepatitis C
• Nonalcoholic Steatohepatitis

Route of Administration

• Oral
• Parenteral
• Others

Diagnosis

• Nonsurgical Tests
• Transient Elastography
• Liver Biopsy
• Others

Treatment

• Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
• ACE Inhibitors
• Hepatotropic Drug
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Liver Fibrosis Market Regional Analysis/Insights

The liver fibrosis market is analysed and market size insights and trends are provided by country, condition, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the liver fibrosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the liver fibrosis market because of the presence of variety of innovative drug molecule to enhance the treatment procedure and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the 'market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to increasing prevalence of liver disorders in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Liver Fibrosis Market Share Analysis

The liver fibrosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to liver fibrosis market.

Some of the major players operating in the liver fibrosis market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (US)
• Bristol-Myers Squibb Company (US)
• Gilead Sciences, Inc. (US)
• Vertex Pharmaceuticals Incorporated (US)
• FibroGen, Inc. (US)
• Pharmaxis Ltd (Australia)
• ディセルナ・ファーマシューティカルズ社（米国）
• ダイナバックス・テクノロジーズ（米国）

SKU-54747